Pilot Study to Estimate a Reduction of TAVR Associated Conduction Disturbance Through Notification of Cara Monitor During TAVR Procedure
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 33
- 试验地点
- 2
- 主要终点
- Evaluate Cara performance in reduction of New Onset Conduction Disturbances (NOCD)
研究概览
简要总结
Prospective, multicenter, roll-in, pilot clinical trial.
Study subjects will be studied during the TAVR procedure and their 12 lead ECGs collected and analyzed for New-Onset Conduction Disturbances (NOCD).
The study will be conducted in two stages:
During the first roll-in stage of the study, 50 intended to undergo TAVR (all comers) will be enrolled.
Data will be collected according to the study schedule below of pre-, during and after the TAVR procedure up to 14 days FU.
This data for the first 50 patients will be analyzed to evaluate the ability of the Cara Monitor prediction of NOCD post TAVR.
The second stage of the stage will be conducted upon completion of the first stage analysis and will be considered to randomize 1:1 the subjects connected to Cara Monitor during the procedure versus site-specific current practice.
The effect of Cara Monitor on reduction of NOCD post TAVR compared to patients treated and followed per regular site-specific practice will be estimated.
详细描述
Data to be collected during the study procedure for both stages:
-
Pre-procedure:
-
Demographics, medical history, cardiac history, medications
-
Cardiac CT raw data to be collected from all the pre-procedure CT scans performed in Medical Centers and from out-of-hospital sources (if available).
-
In hospital 12 lead ECG
-
Procedure:
During the procedure, the 12 lead ECG will be recorded processed, and displayed on the Cara monitor that is connected to Norav NR-1207-3 ECG Holter System. The Hemodynamic and Fluoroscopy monitors will be recorded on a commercially available video recorder. 3. Post-procedure (in hospital)
- After the procedure patients will continue to be connected to a commercially available to a commercially available 14 days ambulatory Holter monitor (AEM) (e.g. Bittium Faros™ ; MoMe™ Kardia) and will remain with the patient after the discharge for 14 days.
- Hospital standard 12 lead ECG will be recorded after the procedure, downloaded and collected by the study team.
- Post-procedure - out of hospital:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must meet be ≥ 18 years of age.
- •Must meet indications for TAVR using approved devices
- •Provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
- •Willing to comply with specified follow-up evaluations.
- •Must meet the legal minimum age to provide Informed Consent based on local regulatory requirements.
排除标准
- •Any implanted device or an indication for treatment with rhythm management device (i.e., pacemaker, Cardiac Resynchronization Therapy (CRT) or Cardiac Resynchronization Therapy with cardioverter-defibrillator (CRT-D) at baseline.
- •Any contraindication to the TAVR procedure according to the instructions for use.
- •Less than the legal age of consent, legally incompetent, or otherwise vulnerable.
- •Planned treatment with any other investigational device, drug, or procedure (excluding registries) during the study period.
结局指标
主要结局
Evaluate Cara performance in reduction of New Onset Conduction Disturbances (NOCD)
时间窗: 14 days
Estimate the reduction of NOCD (percentage) at 14 days post TAVR while using Cara Monitor
Evaluate Cara performance in reduction of Permanent Pacemaker (PPM) or High-Grade AV Block (HGAVB)
时间窗: 14 days
Estimate the reduction (a percentage) of PPM or High-Grade AV Block (HGAVB)
Evaluate Cara usability using a dedicated questioner
时间窗: 1 Day of Procedure
Estimate learning curve of using CaraTM system (e.g. the experience required with system for achieving above improvements)
Evaluate Cara Safety, collecting Adverse Events
时间窗: 14 days
During the study patients will be followed for any adverse events relevant to the TAVR procedure as defined in the CRF
次要结局
未报告次要终点